Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Is specialized palliative cancer care associated with use of antineoplastic treatment at the end of life? A population-based cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{59ad6f41898545fda09841ab28382cd1,
title = "Is specialized palliative cancer care associated with use of antineoplastic treatment at the end of life?: A population-based cohort study",
abstract = "BACKGROUND: The use of chemotherapy in the last 14 days of life should be as low as possible.AIM: To study the factors related to the use of chemotherapy in the last 14 days of life and the factors related to concurrent antineoplastic treatment and specialized palliative care.DESIGN: This was a population-based cohort study. The data were collected from the Danish Register of Causes of Death, the Danish National Patient Register, and the Danish Palliative Care Database. Analyses were descriptive and multivariate logistic regression.SETTING/PARTICIPANTS: Cancer decedents between 2010 and 2013 in the Capital Region of Denmark.RESULTS: During the study period, 17,246 individuals died of cancer and 33% received specialized palliative care. In the last 14 days of life, 4.2% received chemotherapy. Younger patients and patients with hematological cancers were more likely to receive chemotherapy in the last 14 days of life. Receiving specialized palliative care was associated with a lower risk of receiving chemotherapy in the last 14 days of life-odds ratio 0.15 for hospices and 0.53 for palliative hospital units. A total of 8% of the population received concurrent antineoplastic treatment and specialized palliative care. Female gender, younger age, and breast and prostate cancer were significantly associated with this concurrent model.CONCLUSION: Overall, the incidence of antineoplastic treatment in the last 14 days of life was low compared to other studies. Patients in specialized palliative care had a reduced risk of receiving chemotherapy at the end of life.",
author = "{Skov Benthien}, Kirstine and Mathilde Adsersen and Petersen, {Morten Aagaard} and {Soelberg Vadstrup}, Eva and Per Sj{\o}gren and Mogens Groenvold",
year = "2018",
month = oct,
day = "1",
doi = "10.1177/0269216318786393",
language = "English",
volume = "32",
pages = "1509--1517",
journal = "Palliative Medicine",
issn = "0269-2163",
publisher = "Sage Science Press (UK)",
number = "9",

}

RIS

TY - JOUR

T1 - Is specialized palliative cancer care associated with use of antineoplastic treatment at the end of life?

T2 - A population-based cohort study

AU - Skov Benthien, Kirstine

AU - Adsersen, Mathilde

AU - Petersen, Morten Aagaard

AU - Soelberg Vadstrup, Eva

AU - Sjøgren, Per

AU - Groenvold, Mogens

PY - 2018/10/1

Y1 - 2018/10/1

N2 - BACKGROUND: The use of chemotherapy in the last 14 days of life should be as low as possible.AIM: To study the factors related to the use of chemotherapy in the last 14 days of life and the factors related to concurrent antineoplastic treatment and specialized palliative care.DESIGN: This was a population-based cohort study. The data were collected from the Danish Register of Causes of Death, the Danish National Patient Register, and the Danish Palliative Care Database. Analyses were descriptive and multivariate logistic regression.SETTING/PARTICIPANTS: Cancer decedents between 2010 and 2013 in the Capital Region of Denmark.RESULTS: During the study period, 17,246 individuals died of cancer and 33% received specialized palliative care. In the last 14 days of life, 4.2% received chemotherapy. Younger patients and patients with hematological cancers were more likely to receive chemotherapy in the last 14 days of life. Receiving specialized palliative care was associated with a lower risk of receiving chemotherapy in the last 14 days of life-odds ratio 0.15 for hospices and 0.53 for palliative hospital units. A total of 8% of the population received concurrent antineoplastic treatment and specialized palliative care. Female gender, younger age, and breast and prostate cancer were significantly associated with this concurrent model.CONCLUSION: Overall, the incidence of antineoplastic treatment in the last 14 days of life was low compared to other studies. Patients in specialized palliative care had a reduced risk of receiving chemotherapy at the end of life.

AB - BACKGROUND: The use of chemotherapy in the last 14 days of life should be as low as possible.AIM: To study the factors related to the use of chemotherapy in the last 14 days of life and the factors related to concurrent antineoplastic treatment and specialized palliative care.DESIGN: This was a population-based cohort study. The data were collected from the Danish Register of Causes of Death, the Danish National Patient Register, and the Danish Palliative Care Database. Analyses were descriptive and multivariate logistic regression.SETTING/PARTICIPANTS: Cancer decedents between 2010 and 2013 in the Capital Region of Denmark.RESULTS: During the study period, 17,246 individuals died of cancer and 33% received specialized palliative care. In the last 14 days of life, 4.2% received chemotherapy. Younger patients and patients with hematological cancers were more likely to receive chemotherapy in the last 14 days of life. Receiving specialized palliative care was associated with a lower risk of receiving chemotherapy in the last 14 days of life-odds ratio 0.15 for hospices and 0.53 for palliative hospital units. A total of 8% of the population received concurrent antineoplastic treatment and specialized palliative care. Female gender, younger age, and breast and prostate cancer were significantly associated with this concurrent model.CONCLUSION: Overall, the incidence of antineoplastic treatment in the last 14 days of life was low compared to other studies. Patients in specialized palliative care had a reduced risk of receiving chemotherapy at the end of life.

U2 - 10.1177/0269216318786393

DO - 10.1177/0269216318786393

M3 - Journal article

C2 - 30004303

VL - 32

SP - 1509

EP - 1517

JO - Palliative Medicine

JF - Palliative Medicine

SN - 0269-2163

IS - 9

ER -

ID: 55228525